Back to top
more

Envista (NVST)

(Delayed Data from NYSE)

$21.10 USD

21.10
1,979,088

-0.03 (-0.14%)

Updated Sep 16, 2025 03:59 PM ET

After-Market: $21.50 +0.40 (1.90%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 245)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

NuVasive (NUVA) Expands Training Opportunities With New Center

by Zacks Equity Research

NuVasive's (NUVA) East Coast Experience Center reflects the company's commitment to provide best quality surgeon education and training to enhance the standard of patient care in spine surgery.

Zacks Equity Research

Here's Why You Should Add Omnicell (OMCL) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Omnicell (OMCL) on its strategic acquisitions and partnerships supporting each of the three legs of its strategy.

Zacks Equity Research

Here's Why You Should Retain Insulet (PODD) Stock for Now

by Zacks Equity Research

Strong domestic and international performance by Omnipod is driving the top line for Insulet (PODD).

Zacks Equity Research

CVS Health (CVS) Retail Business Grows Despite Cost Pressure

by Zacks Equity Research

CVS Health's (CVS) retail business sees solid rebound in front-store sales with strength across all categories.

Zacks Equity Research

SmileDirectClub (SDC) to Boost Europe Presence, Enter France

by Zacks Equity Research

SmileDirectClub (SDC) since its foray into Europe in 2019 has been seeing remarkable market penetration of its oral care products.

Zacks Equity Research

Neogen (NEOG) Q1 Earnings Top Estimates, Gross Margin Up

by Zacks Equity Research

Strong segmental performance and contributions from new acquisitions and product launches drove Neogen's (NEOG) revenues in the first quarter of fiscal 2022.

Zacks Equity Research

Medtronic (MDT) Starts Pediatric Trial for Scoliosis Treatment

by Zacks Equity Research

Medtronic's (MDT) BRAIVE IDE study will assess the safety and efficacy of growth modulation system in correcting the spine's curve in patients with juvenile or adolescent idiopathic scoliosis.

Zacks Equity Research

Boston Scientific (BSX) Strategic Buyouts Aid Amid Cost Woes

by Zacks Equity Research

Boston Scientific (BSX) is optimistic about its recent deal to acquire Israel-based Lumenis that develops and commercializes energy-based medical solutions.

Zacks Equity Research

NextGen's (NXGN) New Partnership to Boost Patient Experience

by Zacks Equity Research

NextGen (NXGN) collaborates with Clinect Healthcare to extend patient-provider connection.

Zacks Equity Research

Here's Why You Should Invest in Align Technology (ALGN) Now

by Zacks Equity Research

Investors continue to be optimistic about Align Technology (ALGN) on robust second-quarter 2021 performance and raised guidance.

Zacks Equity Research

Boston Scientific's (BSX) New Buyout to Aid Clot Management

by Zacks Equity Research

The acquisition of Devoro Medical by Boston Scientific (BSX) is expected to advance the company's core emphasis on clot management.

Zacks Equity Research

Abbott's (ABT) Portico With FlexNav System Gets FDA Approval

by Zacks Equity Research

Abbott's (ABT) Portico with FlexNav TAVR system is intended to treat people with symptomatic severe aortic stenosis who are at high or extreme risk for open-heart surgery.

Zacks Equity Research

Here's Why You Should Hold on to LHC Group (LHCG) Stock Now

by Zacks Equity Research

LHC Group (LHCG) continues to benefit from strategic deals and broad array of services.

Zacks Equity Research

Here's Why You Should Retain Walgreens (WBA) Stock for Now

by Zacks Equity Research

Investors are optimistic about Walgreens (WBA), given the strong performance in the International segment and notable product launches.

Zacks Equity Research

NEOGEN (NEOG) to Enter Retail Parasiticide Space With New Buyout

by Zacks Equity Research

NEOGEN's (NEOG) acquisition of CAPInnoVet expands its Animal Safety division and offers a strategic entry into the retail parasiticide market.

Zacks Equity Research

Veeva Systems' (VEEV) Cloud Applications Get Adopted by Emmes

by Zacks Equity Research

Veeva Systems' (VEEV) Development Cloud applications to aid in connected drug development.

Zacks Equity Research

Here's Why You Should Hold on to Glaukos (GKOS) Stock Now

by Zacks Equity Research

Glaukos Corporation (GKOS) continues to benefit from robust product portfolio and solid performing iStent technology.

Zacks Equity Research

Fresenius Medical's (FMS) Deal to Boost Home Dialysis in Japan

by Zacks Equity Research

Fresenius Medical (FMS) partners with JMS Co. Ltd. to provide innovative home dialysis therapies to the aging population in Japan to improve their wellbeing.

Zacks Equity Research

Henry Schein (HSIC) Betters Strategic View With Restructure Plan

by Zacks Equity Research

Henry Schein's (HSIC) new organizational structure will continue to enhance the company's exposure to faster-growing and higher-margin markets.

Zacks Equity Research

Here's Why You Should Add IDEXX (IDXX) to Your Portfolio Now

by Zacks Equity Research

Investors are optimistic about IDEXX (IDXX) on strong growth in CAG business and solid global performance.

Zacks Equity Research

Quest Diagnostics' (DGX) COVID-19 Test Demand Up in Q3 Months

by Zacks Equity Research

The "Path Out of the Pandemic" plan of the U.S. Government, while emphasizing more on a magnified access for testing, comes as a major breakthrough for Quest Diagnostics (DGX).

Zacks Equity Research

NextGen's (NXGN) New Collaboration to Boost Solutions Portfolio

by Zacks Equity Research

NextGen (NXGN) and Klamath partner to deliver large-scale COVID-19 vaccinations.

Zacks Equity Research

Stryker's (SYK) Trauma & Extremities Arm Unveils New Product

by Zacks Equity Research

The newly launched Citrelock Tendon Fixation Device System expands Stryker's (SYK) Foot & Ankle offerings.

Zacks Equity Research

Align Technology (ALGN) Launches Professional Whitening System

by Zacks Equity Research

Align Technology's (ALGN) Invisalign Professional Whitening System transforms teeth whitening with an all-in-one solution, enabling Invisalign doctors to straighten and whiten teeth simultaneously.

Zacks Equity Research

OPKO Health (OPK) Forms JV, Establishes Presence in China

by Zacks Equity Research

OPKO Health (OPK) forms a new JV with LeaderMed to establish a presence in China through expansion of the global availability of two of the former's long-acting development products.